- Home
- FOA vs TVRD Comparison
FOA vs TVRD Comparison
Compare FOA & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FOA | TVRD |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 272.8M | 246.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FOA | TVRD |
|---|---|---|
| Price | $23.64 | $4.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $29.75 | ★ $51.67 |
| AVG Volume (30 Days) | 81.1K | ★ 123.7K |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $318,296,000.00 | N/A |
| Revenue This Year | $29.44 | N/A |
| Revenue Next Year | $14.30 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.58 | $3.74 |
| 52 Week High | $32.40 | $43.65 |
Technical Indicators
Market Signals| Indicator | FOA | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 55.50 | 34.35 |
| Support Level | $22.07 | $4.05 |
| Resistance Level | $23.63 | $4.71 |
| Average True Range (ATR) | 0.77 | 0.27 |
| MACD | -0.00 | 0.55 |
| Stochastic Oscillator | 55.93 | 73.20 |
Price Performance
Historical ComparisonAbout FOA Finance of America Companies Inc.
Finance of America Companies Inc is a financial services holding company that, through its operating subsidiaries, is a modern retirement solutions platform that provides customers with access to a range of retirement offerings centered on the home. In addition, FoA offers capital markets and portfolio management capabilities to optimize the distribution of its originated loans to investors. It operates through two segments: Retirement Solutions and Portfolio Management. It generates the majority of its revenue from Retirement Solutions.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.